News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Results From Non-Tuberculous Mycobacteria (NTM) Study Using Aradigm Corporation (ARDM)’s Liposomal Ciprofloxacin To Be Presented At The American Thoracic Society 2014 International Conference


4/15/2014 6:51:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Scientists from the Oregon State University, Corvallis (OSU) and Aradigm Corporation (OTCBB: ARDM) (the “Company”) demonstrated that after 4 days of in vitro treatment of macrophages infected with Mycobacterium avium and Mycobacterium abscessus, Aradigm’s liposomal ciprofloxacin was associated with a decrease of greater than 99% of these infections at ciprofloxacin concentrations of 200 mcg/ml, which approximate the peak sputum levels observed in humans in prior Aradigm clinical studies.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES